A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age The objective of the study is to evaluate the general safety of ZOSTAVAX™ in subjects ≥60 years of age.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin After 20 weeks, to assess the effect of treatment with MK-0941 compared with placebo on A1C when added to basal insulin.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancer 1. To evaluate and compare PFS per RECIST 1.1 as assessed by BICR in subjects. treated with pembrolizumab plus axitinib versus sunitinib monotherapy. 2. To evaluate and compare OS in subjects treated ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

First Extension (018-06(PL_3)): A Blinded Extension to 5 Years for: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium Second Extension (018-20(PL_1)): A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium Second Extension (018-21(PL_2)): An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium First Extension To assess the effect of treatment up to 5 years with odanacatib on the risk of morphometrically assessed vertebral fractures compared to placebo. To assess the effect of treatment up ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio multicéntrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con Prevenar 13™ en lactantes sanos";"A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13™ in Healthy Infants (1) Objetivo: demostrar que la vacuna antineumocócica conjugada 15 valente (V114) con aluminio como adyuvante o V114 sin adyuvante no es inferior a la vacuna antineumocócica conjugada 13 valente (Prev...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Estudio Global VerICiguaT en sujetos con insuficiencia cardíaca con fracción de eyección reducida (Victoria) To evaluate the efficacy of the oral soluble guanylate cyclase (sGC) stimulator MK-1242 (vericiguat) in comparison to placebo on a background of standard of care in increasing the time to first occurr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubicin and Docetaxel in Breast Cancer Patients 1) To compare DSN, defined as the number of days with ANC < 0.5 x 109/L, during Cycle 1, in patients with breast cancer receiving MK-4214 or Neupogen™ as adjunct to chemotherapy with doxorubicin in co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Open-Label, Pharmacokinetics Study of Caspofungin in Neonates and Infants To evaluate and compare Day 1 C24 hr caspofungin plasma concentrations obtained from neonates and infants <3 months of age administered caspofungin at a 25-mg/m2 intravenous (IV) dose to historical da...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

MK- 0542B-PN 143 Research study that will test the safety & efficacy of combining extended release niacin + laropiprant + simvastatin (MK-0524B) in the management of cholesterol levels Evaluate the LDL-C-lowering effects of ERN/LRPT/SIM 2 g/20 mg compared to ERN/LRPT 2 g coadministered with simvastatin 20 mg. Hypothesis: ERN/LRPT/SIM 2 g/20 mg is equivalent to ERN/LRPT 2 g coadmini...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Single Dose Study to Assess the Biocomparison of MK-8669 in Subjects To evaluate the whole blood pharmacokinetics and comparative bioavailability (AUC0-∞, Cmax, Tmax and apparent t1/2) of 2 new granule formulations of ridaforolimus compared to the provisional market 10...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune